Szczegóły publikacji
Opis bibliograficzny
Positive antiphospholipid antibodies increase the risk of ischemic stroke in patients with atrial fibrillation / Maksymilian Hanarz, Michał Ząbczyk, Joanna Natorska, Mateusz BARAN, Anetta Undas // Journal of Thrombosis and Haemostasis ; ISSN 1538-7933. — 2024 — vol. 22 iss. 10, s. 2797–2809. — Bibliogr., Abstr. — Publikacja dostępna online od: 2024-06-27
Autorzy (5)
- Hanarz Maksymilian
- Ząbczyk Michał
- Natorska Joanna
- AGHBaran Mateusz
- Undas Anetta
Słowa kluczowe
Dane bibliometryczne
| ID BaDAP | 156206 |
|---|---|
| Data dodania do BaDAP | 2024-11-21 |
| DOI | 10.1016/j.jtha.2024.05.038 |
| Rok publikacji | 2024 |
| Typ publikacji | artykuł w czasopiśmie |
| Otwarty dostęp |  |
| Czasopismo/seria | Journal of Thrombosis and Haemostasis |
Abstract
Background: Antiphospholipid antibodies (aPL), including lupus anticoagulant, antibodies against β2 glycoprotein I (anti-β2GPI), and anticardiolipin (aCL) antibodies are associated with ischemic stroke (IS). Their prevalence and clinical relevance in atrial fibrillation (AF) remain unclear. Objectives: To assess whether aPL are associated with increased risk of IS in AF patients despite anticoagulation. Methods: We conducted a post hoc analysis of aPL using blood samples from 243 consecutive AF patients enrolled in a cohort study. Markers of a prothrombotic state, including endogenous thrombin potential, fibrin clot permeability, and lysis time, were measured at baseline. During a median follow-up of 52 months, IS/transient ischemic attack and major bleeding were recorded. Results: We observed aPL at a moderate or high titer in 51 (21%) patients, including 17 (7%) with anti-β2GPI, 19 (7.8%) with aCL antibodies, and 37 (15.2%) with lupus anticoagulant. aPL-positive patients were more likely to have prior stroke (P = .01) and be active smokers (P = .03), along with increased endogenous thrombin potential (P = .02), without any changes in fibrin clot properties. Anti-β2GPI (hazard ratio, 4.38; 95% CI, 1.58-12.19) and aCL (hazard ratio, 4.70; 95% CI, 1.80-12.30) at a moderate or high titer were associated with IS during follow-up (n = 20; 1.9% per year). There were 23 major bleedings (2.1% per year) and 20 deaths (1.9% per year), which were not associated with aPLs. Conclusion: Our study showed a relatively high prevalence of aPL positivity in AF patients, which was linked to an increased risk of IS/transient ischemic attack. This suggests that screening for aPL might help optimize anticoagulant therapy in such patients.
